DCTN1 Human shRNA Lentiviral Particle (Locus ID 1639)

CAT#: TL305084V

DCTN1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL305084B virus into HEK293 cells. TL305084B virus was prepared using lenti-shRNA TL305084B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL305084C] virus into HEK293 cells. [TL305084C] virus was prepared using lenti-shRNA [TL305084C] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 1639
• Synonyms: DAP-150; DP-150; P135
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001135040, NM_001135041, NM_001190836, NM_001190837, NM_004082, NM_023019, NR_033935, NM_004082.1, NM_004082.2, NM_004082.3, NM_004082.4, NM_023019.1, NM_023019.2, NM_023019.3, NM_001135041.1, NM_001135041.2, NM_001135040.1, NM_001135040.2, NM_001190836.1, NM_001190837.1, BC071583, BC006163, BC013978, NM_001190837.2, NM_004082.5, NM_001135041.3, NM_001190836.2, NM_023019.4, NM_001135040.3
• UniProt ID: Q14203
• Summary: This gene encodes the largest subunit of dynactin, a macromolecular complex consisting of 10 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein. Dynactin is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit interacts with dynein intermediate chain by its domains directly binding to dynein and binds to microtubules via a highly conserved glycine-rich cytoskeleton-associated protein (CAP-Gly) domain in its N-terminus. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. Mutations in this gene cause distal hereditary motor neuronopathy type VIIB (HMN7B) which is also known as distal spinal and bulbar muscular atrophy (dSBMA). [provided by RefSeq, Oct 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).